Largest Phase 3 trial of Ibrance in early breast cancer opens
26 August 2015 | By Victoria White
Alliance Foundation Trials, the Austrian Breast & Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study...
List view / Grid view
News
NICE recommends vedolizumab for Crohn’s Disease
26 August 2015 | By Victoria White
NICE has recommended Vedolizumab, the first gut-selective treatment for Crohn's Disease, for use on the NHS, recognising the innovation of the treatment...
NICE recommends edoxaban for deep vein thrombosis
26 August 2015 | By Victoria White
NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS...
Operational cost savings for Perrigo UK
25 August 2015 | By CI Precision
Perrigo UK recently installed three SP-4C tablet and capsule sample weight checkers from specialist weighing equipment manufacturer CI Precision...
Study raises doubt about health benefits of omega-3
25 August 2015 | By Victoria White
A large clinical trial by researchers at the National Institutes of Health has found that omega-3 supplements did not slow cognitive decline in older people...
Brazil’s pharmaceutical market to continue to prosper
25 August 2015 | By Victoria White
Brazil's pharmaceutical market will expand to reach approximately $47.9 billion by 2020, according to research and consulting firm GlobalData...
FDA approves label expansion for Promacta
25 August 2015 | By Victoria White
The FDA has approved a label expansion for Promacta to treat low blood platelet count in paediatric patients with chronic immune thrombocytopenic purpura...
Disappointing results for liraglutide in type 1 diabetes
25 August 2015 | By Victoria White
Novo Nordisk has announced headline results from the final Phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes...
Data findings highlight common misconceptions about concussion
24 August 2015 | By Victoria White
New data from Abbott's Concussion IQ Survey reveals that many adults lack basic understanding about concussion signs, symptoms, risk and treatment...
Phase III study data for Fycompa in PGTC seizures published
24 August 2015 | By Victoria White
Phase III study results for Eisai’s Fycompa® (perampanel) in primary generalised tonic-clonic (PGTC) seizures have been published for the first time...
Real world ETNA registries of new once-daily edoxaban start in Europe
24 August 2015 | By Victoria White
ETNA registries have commenced in Europe to collect a robust set of information on how once-daily edoxaban is being used in real world settings...
Bavituximab and durvalumab combo to be evaluated in solid tumours
24 August 2015 | By Victoria White
AstraZeneca and Peregrine Pharmaceuticals are to evaluate the safety and efficacy of Peregrine’s bavituximab in combination with AstraZeneca’s durvalumab...
Positive topline results from two Phase 3 studies of Trumenba
21 August 2015 | By Victoria White
Pfizer has announced positive topline results of two Phase 3 studies of Trumenba (Meningococcal Group B Vaccine). Both studies met all primary endpoints...
Novartis pays $1 billion to bolster its pipeline with ofatumumab
21 August 2015 | By Victoria White
Novartis is to acquire all remaining rights to GSK's ofatumumab to develop treatments for MS and other autoimmune indications...
Janssen submits Extension MAA for paliperidone palmitate once-every-three-months formulation
21 August 2015 | By Victoria White
Janssen has submitted an Extension MAA to the EMA for paliperidone palmitate once-every-three-months formulation for the treatment of schizophrenia...
